Literature DB >> 12839929

Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells.

Steven C Fausch1, Diane M Da Silva, W Martin Kast.   

Abstract

A causal link between cervical cancer and high-risk human papillomaviruses has been established. The virus infects basal cells of the mucosa, where Langerhans cells are the resident antigen-presenting cells. Langerhans cells and dendritic cells, which are targeted by vaccination, internalize similar amounts of human papillomavirus virus-like particles (VLPs), albeit through different uptake mechanisms. VLP uptake by dendritic cells results in activation and cross-presentation of MHC class I-restricted peptides with costimulation to T cells. Conversely, VLP uptake by Langerhans cells leads to cross-presentation in the absence of costimulation. Efficient VLP cross-presentation by Langerhans cells with costimulation can be achieved by addition of CD40 ligand. The lack of a protective immune response after viral contact with Langerhans cells may explain why some women fail to mount an immune response against the virus or why the immune responses that do develop may allow the virus to persist. Because VLPs are currently being tested as a vaccine against cervical cancer, our data are very topical and have implications for optimal vaccination strategies against this disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839929

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

Authors:  L Buonaguro; M L Tornesello; M Tagliamonte; R C Gallo; L X Wang; R Kamin-Lewis; S Abdelwahab; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 2.  Design opportunities for actively targeted nanoparticle vaccines.

Authors:  Tarek M Fahmy; Stacey L Demento; Michael J Caplan; Ira Mellman; W Mark Saltzman
Journal:  Nanomedicine (Lond)       Date:  2008-06       Impact factor: 5.307

3.  Functional analysis of HPV-like particle-activated Langerhans cells in vitro.

Authors:  Lisa Yan; Andrew W Woodham; Diane M Da Silva; W Martin Kast
Journal:  Methods Mol Biol       Date:  2015

4.  Molecular analysis of human papillomavirus virus-like particle activated Langerhans cells in vitro.

Authors:  Andrew W Woodham; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  Methods Mol Biol       Date:  2015

Review 5.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

6.  Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Authors:  Diane M Da Silva; Carly A Movius; Adam B Raff; Heike E Brand; Joseph G Skeate; Michael K Wong; W Martin Kast
Journal:  Virology       Date:  2014-02-17       Impact factor: 3.616

7.  Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

8.  Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses.

Authors:  Julia Kim; Vandana Gambhir; Attiya Alatery; Sameh Basta
Journal:  J Biomed Biotechnol       Date:  2010-05-23

Review 9.  HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.

Authors:  Luciano Mariani; Aldo Venuti
Journal:  J Transl Med       Date:  2010-10-27       Impact factor: 5.531

Review 10.  Mechanisms of cell entry by human papillomaviruses: an overview.

Authors:  Caroline A J Horvath; Gaëlle A V Boulet; Virginie M Renoux; Philippe O Delvenne; John-Paul J Bogers
Journal:  Virol J       Date:  2010-01-20       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.